Biogen (BIIB)
| Company | Ticker | Sector | Industry | Quality | PAR |
|---|---|---|---|---|
| Biogen | BIIB | Healthcare | Drug Manufacturers - General | 76 | 13.1% |
| Current Price (11/24) | $242.51 | |||
| CAPS Rating (Rate this stock on CAPS) |  |
|||
| Expected Income Statement | ||||
| Current Sales | 14,263.3 | |||
| Sales Growth Forecast | 4.0% | |||
| Net Profit Margin | 27.8% | |||
| Projected Shares Outstanding | 140.00 | |||
| EPS - Five year Forecast | $34.48 | |||
| Average P/E Ratio | 13.0 | |||
| Projected Average Price | $448.26 | |||
| Price Appreciation (Annualized) | 13.1% | |||
| Annual Dividend Yield | 0.0% | |||
| Projected Annual Return | 13.1% | |||
| Quality | ||||
| Financial Strength | 68 | 17.0 | ||
| EPS Stability | 84 | 21.0 | ||
| Industry Sales Growth Rate | 8.0% | 6.3 | ||
| Industry Net Profit Margin | 22.5% | 15.4 | ||
| Calculated Quality Rating | 59.6 | |||
| Fool CAPS | ||||
Total Players
979
Outperforms
72
Underperforms
All-Stars (227)
213
Outperforms (94%)
14
Underperforms
|
||||
| Fundamental Data Updated: 10/02/2020 | ||||